Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
PR Newswire•11/11/2026•08:30 ET
0
Key Highlights
- ➤Citius Pharma CEO Leonard Mazur will host one-on-one business development meetings in London
- ➤Citius Oncology (CTOR) continues commercializing LYMPHIR, launched in December 2025
- ➤LYMPHIR treats adults with relapsed or refractory Stage I–III CTCL after prior systemic therapy
- ➤Management estimates LYMPHIR’s initial market currently exceeds $400 million
- ➤Citius Pharma owns approximately 71% of Citius Oncology
Expert Statements
Leonard Mazur, Chairman and Chief Executive Officer of Citius Pharmaceuticals
“Mr. Mazur will provide an overview of the Company's business and recent developments, including the ongoing commercialization of LYMPHIR(®) (denileukin diftitox-cxdl) by the Company's majority-owned subsidiary, Citius Oncology, Inc.”
Citius Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London PR Newswire
Chairman and CEO Leonard Mazur to host one-on-one business development meetings
Get started
Create a free account to read the full story.